天眼查数据显示，武田（中国）国际贸易有限公司成立日期2012年09月12日，法定代表人刘燕，所属行 业为医疗用品及器材批发，企业类型为有限责任公司(外商投资、非独资)，企业规模为大型，参保人数 1192，注册资本2150万美元，实缴资本840万美元，注册地址为中国（上海）自由贸易试验区美盛路56 号2层220室。股东信息如下： 股东名称持股比例认缴出资额认缴出资日期首次持股日期武田（中国）投资有限公司74.4186%1600万 美元2018年9月11日2012年09月12日Takeda Pharmaceuticals International AG25.5814%550万美元2023年7 月21日2023年03月13日 来源：新浪财经-鹰眼工作室 国家药品监督管理局药品审评中心数据显示，2025年12月13日，Vetter Pharma-Fertigung GmbH & Co. KG的拉那利尤单抗注射液申请已获受理，受理号为JTS2500165。 受理号JTS2500165药品名称拉那利尤单抗注射液药品类型申请类型进口注册分类生物制品企业名称 Vetter Pharma-Fertigung GmbH & C ...

Core Viewpoint - The article discusses the upcoming IPOs of two companies: Jianfa Zhixin and Jinhua New Materials, highlighting their business models, financial metrics, and market positions in their respective industries [1][10]. Group 1: Jianfa Zhixin (301584.SZ) - Jianfa Zhixin is a national high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables [1][6]. - The company is controlled by Xiamen Jianfa Group, with a 51.02% stake held by Jianfa Medical, which is fully owned by Xiamen Jianfa Group [6]. - For 2024, Jianfa Zhixin's revenue is projected to be divided into three segments: direct sales (110.32 billion, 61.69%), distribution (67.38 billion, 37.68%), and service (1.12 billion, 0.63%) [6]. - The company serves over 3,300 medical institutions across 31 provinces, with major clients including Beijing Anzhen Hospital and Jilin University First Hospital [6]. - Jianfa Zhixin's fundraising will focus on upgrading information systems (1.4 billion), centralized operation services (1.04 billion), and working capital (2.4 billion) [5]. Group 2: Jinhua New Materials (920015.BJ) - Jinhua New Materials specializes in the research, production, and sales of ketoxime series fine chemicals, being a leading player in the domestic silane crosslinker segment [10][11]. - The company plans to invest in several projects, including a high-end coupling agent project (5.07 billion) and a ketone-based smart factory construction project (0.61 billion) [10]. - Jinhua New Materials holds a market share of 27.85%, 31.60%, and 38.16% in silane crosslinkers for the years 2022, 2023, and 2024, respectively [11]. - The company has received multiple honors, including being recognized as a "Little Giant" enterprise and a national high-tech enterprise [11]. - Jinhua New Materials faces potential risks from cyclical fluctuations in downstream industries, particularly in real estate and photovoltaic sectors, which may impact demand for its products [12].